Firazyr tested in kids with rare swelling disorder
NCT ID NCT05509569
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study in Japan looked at 32 children (ages 2 to under 18) with hereditary angioedema who received Firazyr injections for acute attacks. Researchers tracked side effects and how quickly symptoms resolved over 3 months. The goal was to gather real-world safety and effectiveness data in pediatric patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Icatibant (Firazyr) injection
- What this could lead to
- If results are positive, it could confirm that Firazyr is a safe and effective option for treating acute HAE attacks in children.
- What could go wrong
- This is a small, observational study in Japan only, with no control group. It cannot prove effectiveness and may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda selected site
Tokyo, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients
- Takhzyro under the microscope: Real-World safety check for rare swelling disease
- New hope for HAE patients: experimental drug aims to slash attack rate
- New RNA drug shows promise in preventing HAE attacks in ongoing study
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder